[Carbapenem antibiotics].
Watanabe
Akira
A
Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging and Cancer, Tohoku University.
D021581:Active Transport, Cell Nucleus; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy; D001426:Bacterial Proteins; D015780:Carbapenems / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D002352:Carrier Proteins / Q000378:metabolism; D002463:Cell Membrane Permeability; D015195:Drug Design; D004352:Drug Resistance, Microbial; D004355:Drug Stability; D006602:Hexosyltransferases; D006801:Humans; D002267:Muramoylpentapeptide Carboxypeptidase / Q000378:metabolism; D046915:Penicillin-Binding Proteins; D010458:Peptidyl Transferases; D011550:Pseudomonas aeruginosa / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D013329:Structure-Activity Relationship; D001618:beta-Lactamases
D001426:Bacterial Proteins; D015780:Carbapenems; D002352:Carrier Proteins; D046915:Penicillin-Binding Proteins; D010458:Peptidyl Transferases; D006602:Hexosyltransferases; D002267:Muramoylpentapeptide Carboxypeptidase; D001618:beta-Lactamases